Your AI-Trained Oncology Knowledge Connection!
The safety run-in of the LEAP-014 trial showed acceptable toxicity and antitumor responses in patients with metastatic esophageal cancer receiving pembrolizumab, lenvatinib, and chemotherapy consisting of cisplatin plus either paclitaxel or 5-fluororacil.
An exploratory analysis of Study 309/KEYNOTE-775 showed further benefit for patients and consistent safety in patients who received pembrolizumab plus lenvatinib for advanced endometrial cancer who continued lenvatinib treatment.
A novel CD20xCD3 bispecific antibody showed promising safety and preliminary antitumor activity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Treatment with datopotamab deruxtecan led to a statistically significant and clinically meaningful improvement in progression-free survival in patients with metastatic hormone receptor-positive breast cancer.
In the phase 3 CLEAR study, lenvatinib combined with pembrolizumab continued to elicit deep and durable tumor response among patients with advanced clear cell renal cell carcinoma.
Findings from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial showed that patients with dMMR/MSI-H had a progression-free survival rate of 57.0% in the dostarlimab arm vs 10.2% in the placebo arm.
Enfortumab vedotin-ejfv plus pembrolizumab improves survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
At a median follow-up of 13.9 months, patients with extra-pancreatic NETs treated with cabozantinib experienced a median progression-free survival of 8.3 months vs 3.2 months with placebo.
The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Data presented at the 2023 ESMO Congress and showed that induction chemotherapy followed by chemoradiation reduced the risk of progression or death by 35% vs chemoradiation alone in patients with cervical cancer.
Tisotumab vedotin-tftv improved survival in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.
In the phase 2 DESTINY-PanTumor01 trial, trastuzumab deruxtecan showed clinically meaningful pan-tumor activity in patients with a range of solid tumors harboring HER2 mutations.
The addition of nivolumab to frontline standard of care gemcitabine-cisplatin, followed by nivolumab maintenance therapy, led to statistically significant and clinically meaningful improvements in survival compared with gemcitabine-cisplatin alone in patients with unresectable or metastatic urothelial carcinoma.
Adding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
The addition of pembrolizumab to enzalutamide did not improve survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer.
Thomas Powles, MD, MBBS, MRCP, discusses findings from the phase 3 EV-302 clinical trial of enfortumab vedotin-ejfv with pembrolizumab vs chemotherapy for the treatment of patients with previously untreated locally advanced or metastatic urothelial cancer.
A trial comparing selpercatinib with cabozantinib or vandetanib led to greater benefit and favorable safety in the selpercatinib arm, supporting use of the selective RET inhibitor as first-line treatment for patients with advanced RET-mutant medullary thyroid cancer, according to interim data presented at the 2023 ESMO Congress.
Combining amivantamab, carboplatin, and pemetrexed in patients with non–small cell lung cancer and an EGFR exon 20 insertion led to improved progression-free survival, overall response rate, duration of response, and a trend toward overall survival benefit vs chemotherapy alone in the randomized phase 3 PAPILLON study.
Results phase 3 LIBRETTO-431 trial presented at the 2023 ESMO Congress showed selpercatinib monotherapy demonstrated better survival results than chemotherapy with or without pembrolizumab for patients with RET fusion–positive non–small cell lung cancer.
Results from the phase 3 ALINA trial showed the benefit of ALK inhibition for patients with ALK-positive, early-stage, non–small-cell lung cancer with use of adjuvant alectinib significantly improving disease-free survival.
Results of from a subgroup of patients in the phase 2 C-144-01 study with advanced mucosal melanoma showed a clinically meaningful response to lifileucel after progression on immune checkpoint inhibitors.
The emergence of preliminary efficacy evidence, and potential biomarker targets, with the combination of the novel anti-TGIT agent etigilimab and nivolumab was presented at the 2023 ESMO Congress.
In the first phase 3 perioperative study of patients with resectable non–small cell lung cancer given adjuvant nivolumab after surgery and a prior regimen of nivolumab and chemotherapy showed improved event-free survival results.
Findings from the FLAURA2 trial demonstrate that firstline treatment with osimertinib plus chemotherapy reduced the risk for central nervous system progression in patients with EGFR-positive non-small cell lung cancer.
Adding durvalumab to chemotherapy, followed by durvalumab and olaparib maintenance therapy improved progression-free survival in newly diagnosed advanced or recurrent endometrial cancer.
Belzutifan led to improved progression-free survival and objective response rate compared to everolimus for patients with advanced clear cell renal cell carcinoma, according to study findings.
One-year follow-up of the phase 2 study assessing the use of neoadjuvant and adjuvant cemiplimab in patients with cutaneous squamous cell carcinoma shows a promising survival benefit that has led to a wider phase 3 study.
Findings from a recent analysis of the DESTINY-Breast04 trial demonstrate improvement in efficacy when trastuzumab deruxtecan monotherapy is used for patients with HER2-low metastatic breast cancer.
Progression-free survival in the central nervous system appears to be longer with trastuzumab deruxtecan than with comparator treatment in patients with HER2-positive metastatic breast cancer and brain metastases.
